Listen Now
Topics Covered
- Overview of Waldenstrom’s Macroglobulinemia, including Staging, in the Context of COVID-19
- Symptoms & Signs
- Front Line Treatment for WM
- Treatment for Relapsed/Refractory WM
- New Treatment Approaches
- Translating Genomic Findings into New Treatment Opportunities for WM
- Clinical Trials, in the Context of COVID-19
- Controlling Symptoms & Treatment Side Effects, including Reducing Complications
- Peripheral Neuropathy
- Follow-Up Care
- Communicating with Your Health Care Team about Your Quality-of-Life Concerns
- Guidelines to Prepare for Telehealth/Telemedicine Appointments
- Questions for Our Panel of Experts
Our Panel of Experts
Stephen Ansell, MD, PhD
Professor of Medicine, Mayo Clinic College of Medicine, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic
Jorge J. Castillo, MD
Clinical Director, Bing Center for Waldenstrom’s Macroglobulinemia, Physician, Dana-Farber Cancer Institute, Associate Professor, Harvard Medical School
Steven Treon, MD, PhD
Director, Bing Center for Waldenstrom’s Macroglobulinemia, Senior Physician, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
Andrew Branagan, MD, PhD
Attending Physician, Massachusetts General Hospital Cancer Center, Harvard Medical School
Peter DeNardis
IWMF Chair of the Board of Trustees, The International Waldenstrom’s Macroglobulinemia Foundation (IWMF)
Carolyn Messner, DSW, BCD, FAPOS, FAOSW
Director of Education and Training, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on April 21, 2021.